Drug resistance in Cryptococcus neoformans

被引：82

作者：

Perfect, JR ^{[1
]}

Cox, GM ^{[1
]}

机构：

[1] Duke Univ, Med Ctr, Dept Med, Div Infect Dis, Durham, NC 27710 USA

来源：

DRUG RESISTANCE UPDATES | 1999年 / 2卷 / 04期

关键词：

D O I：

10.1054/drup.1999.0090

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Cryptococcus neoformans has become a major opportunistic fungal pathogen worldwide. Successful treatment of invasive disease with this fungus has used amphotericin B, flucytosine and various azoles. However, treatment failures continue to occur for a variety of reasons including direct antifungal drug resistance. Issues and mechanisms for antifungal drug resistance in Cryptococcus neoformans are reviewed. Furthermore, approaches and strategies for prevention and treatment of antifungal drug resistance are identified and these include host immune modulation, dose optimization, prophylaxis/empirical regimens, improved drug delivery systems such as lipid preparations of amphotericin B, surgery, combination antifungal treatments and development of new antifungal agents. (C) 1999 Harcourt Publishers Ltd.

引用

页码：259 / 269

页数：11

共 126 条

[1]

ABLHANNA P, 1998, 36 INF DIS SOC M DEN

[2] Evaluation of the echinocandin antifungal MK-0991 (L-743,872): Efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis [J].

Abruzzo, GK ;

Flattery, AM ;

Gill, CJ ;

Kong, L ;

Smith, JG ;

Pikounis, VB ;

Balkovec, JM ;

Bouffard, AF ;

Dropinski, JF ;

Rosen, H ;

Kropp, H ;

Bartizal, K .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (11) :2333-2338

[3] Antifungal resistance trends towards the year 2000 - Implications for therapy and new approaches [J].

Alexander, BD ;

Perfect, JR .

DRUGS, 1997, 54 (05) :657-678

[4] COMBINED THERAPY WITH FLUCONAZOLE AND FLUCYTOSINE IN MURINE CRYPTOCOCCAL MENINGITIS [J].

ALLENDOERFER, R ;

MARQUIS, AJ ;

RINALDI, MG ;

GRAYBILL, JR .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (04) :726-729

[5]

Alves Sydney H., 1997, Revista do Instituto de Medicina Tropical de Sao Paulo, V39, P359, DOI 10.1590/S0036-46651997000600010

[6] Microdilution antifungal susceptibility testing of Candida albicans and Cryptococcus neoformans with and without agitation: An eight-center collaborative study [J].

Anaissie, EJ ;

Paetznick, VL ;

Ensign, LG ;

EspinelIngroff, A ;

Galgiani, JN ;

Hitchcock, CA ;

LaRocco, M ;

Patterson, T ;

Pfaller, MA ;

Rex, JH ;

Rinaldi, MG .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (10) :2387-2391

[7] Possible development of resistance to fluconazole during suppressive therapy for AIDS-associated cryptococcal meningitis [J].

Armengou, A ;

Porcar, C ;

Mascaro, J ;

GarciaBragado, F .

CLINICAL INFECTIOUS DISEASES, 1996, 23 (06) :1337-1338

[8] EFFECT OF PENTAMIDINE ON THE GROWTH OF CRYPTOCOCCUS-NEOFORMANS [J].

BARCHIESI, F ;

DELPOETA, M ;

MORBIDUCCI, V ;

ANCARANI, F ;

SCALISE, G .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1994, 33 (06) :1229-1232

[9] In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872) [J].

Bartizal, K ;

Gill, CJ ;

Abruzzo, GK ;

Flattery, AM ;

Kong, L ;

Scott, PM ;

Smith, JG ;

Leighton, CE ;

Bouffard, A ;

Dropinski, JF ;

Balkovec, J .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (11) :2326-2332

[10] FLUCYTOSINE [J].

BENNETT, JE .

ANNALS OF INTERNAL MEDICINE, 1977, 86 (03) :319-322

← 1 2 3 4 5 6 7 8 9 10 →